doi: 10.1161/hq1201.100260
© 2001 American Heart Association, Inc.
Atherosclerosis and Lipoproteins |
Ezetimibe, a Potent Cholesterol Absorption Inhibitor, Inhibits the Development of Atherosclerosis in ApoE Knockout Mice
From the Department of Central Nervous System and Cardiovascular Research, Schering-Plough Research Institute, Kenilworth, NJ.
Correspondence to Harry R. Davis, Jr, K-15-2/2600, Schering-Plough Research Institute, 2015 Galloping Hill Rd, Kenilworth, NJ 07033. E-mail harry.davis{at}spcorp.com
Ezetimibe (SCH58235) is a potent, selective, cholesterol absorption inhibitor. The objective of this study was to determine whether ezetimibe reduces plasma cholesterol and inhibits atherogenesis in apolipoprotein E knockout (apoE-/-) mice. Cholesterol absorption was inhibited by >90% at doses of ezetimibe >3 mg/kg in apoE-/- mice. Atherosclerosis and lipoprotein changes were determined in apoE-/- mice fed a high-fat (0.15% cholesterol) "western" diet, a low-fat (0.15% cholesterol) diet, or a semisynthetic cholesterol-free diet with or without ezetimibe (5 mg/kg per day) for 6 months. Ezetimibe reduced plasma cholesterol levels from 964 to 374 mg/dL, from 726 to 231 mg/dL, and from 516 to 178 mg/dL in the western, low-fat, and cholesterol-free diet groups, respectively. The reductions occurred in the very low density and low density lipoprotein fractions, whereas high density lipoprotein cholesterol levels were increased by ezetimibe treatment. Ezetimibe reduced aortic atherosclerotic lesion surface area from 20.2% to 4.1% in the western diet group and from 24.1% to 7.0% in the low-fat cholesterol diet group. Ezetimibe reduced carotid artery atherosclerotic lesion cross-sectional area by 97% in the western and low-fat cholesterol groups and by 91% in the cholesterol-free group. Ezetimibe inhibits cholesterol absorption, reduces plasma cholesterol, increases high density lipoprotein levels, and inhibits the progression of atherosclerosis under western, low-fat, and cholesterol-free dietary conditions in apoE-/- mice. Although apoE-/- mice are more hypercholesterolemic than are humans and low density lipoprotein reductions with ezetimibe are not as pronounced clinically, ezetimibe may inhibit atherogenesis in individuals consuming restricted-fat or western diets.
Key Words: cholesterol absorption • ezetimibe • atherosclerosis • hypercholesterolemia
This article has been cited by other articles:
 |
|
 |
|
  M. E. Greenberg, J. D. Smith, and E. Sehayek Moderately Decreased Cholesterol Absorption Rates Are Associated With a Large Atheroprotective Effect Arterioscler Thromb Vasc Biol, November 1, 2009; 29(11): 1745 - 1750. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Nomura, H. Ishii, A. Kawakami, and M. Yoshida Inhibition of hepatic Niemann-Pick C1-like 1 improves hepatic insulin resistance Am J Physiol Endocrinol Metab, November 1, 2009; 297(5): E1030 - E1038. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. B. Hartman, S. J. Gardell, C. J. Petucci, S. Wang, J. A. Krueger, and M. J. Evans Activation of farnesoid X receptor prevents atherosclerotic lesion formation in LDLR-/- and apoE-/- mice J. Lipid Res., June 1, 2009; 50(6): 1090 - 1100. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Silbernagel, G. Fauler, W. Renner, E. M. Landl, M. M. Hoffmann, B. R. Winkelmann, B. O. Boehm, and W. Marz The relationships of cholesterol metabolism and plasma plant sterols with the severity of coronary artery disease J. Lipid Res., February 1, 2009; 50(2): 334 - 341. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. D. Labonte, L. M. Camarota, J. C. Rojas, R. J. Jandacek, D. E. Gilham, J. P. Davies, Y. A. Ioannou, P. Tso, D. Y. Hui, and P. N. Howles Reduced absorption of saturated fatty acids and resistance to diet-induced obesity and diabetes by ezetimibe-treated and Npc1l1-/- mice Am J Physiol Gastrointest Liver Physiol, October 1, 2008; 295(4): G776 - G783. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. H. DAVIDSON Is ezetimibe/simvastatin no better than simvastatin alone? Lessons learned and clinical implications Cleveland Clinic Journal of Medicine, July 1, 2008; 75(7): 479 - 496. [Full Text] [PDF]
|
|
|
|
|
|
E. Sehayek and S. L. Hazen Cholesterol Absorption From the Intestine Is a Major Determinant of Reverse Cholesterol Transport From Peripheral Tissue Macrophages Arterioscler Thromb Vasc Biol, July 1, 2008; 28(7): 1296 - 1297. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Wohlfart, H. Xu, A. Endlich, A. Habermeier, E. I. Closs, T. Hubschle, C. Mang, H. Strobel, T. Suzuki, H. Kleinert, et al. Antiatherosclerotic Effects of Small-Molecular-Weight Compounds Enhancing Endothelial Nitric-Oxide Synthase (eNOS) Expression and Preventing eNOS Uncoupling J. Pharmacol. Exp. Ther., May 1, 2008; 325(2): 370 - 379. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. A. Valasek, S. L. Clarke, and J. J. Repa Fenofibrate reduces intestinal cholesterol absorption via PPAR{alpha}-dependent modulation of NPC1L1 expression in mouse J. Lipid Res., December 1, 2007; 48(12): 2725 - 2735. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Zadelaar, R. Kleemann, L. Verschuren, J. de Vries-Van der Weij, J. van der Hoorn, H. M. Princen, and T. Kooistra Mouse Models for Atherosclerosis and Pharmaceutical Modifiers Arterioscler Thromb Vasc Biol, August 1, 2007; 27(8): 1706 - 1721. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. R. Davis Jr, L. M. Hoos, G. Tetzloff, M. Maguire, L.-j. Zhu, M. P. Graziano, and S. W. Altmann Deficiency of Niemann-Pick C1 Like 1 Prevents Atherosclerosis in ApoE-/- Mice Arterioscler Thromb Vasc Biol, April 1, 2007; 27(4): 841 - 849. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Basso, L. A. Freeman, C. Ko, C. Joyce, M. J. Amar, R. D. Shamburek, T. Tansey, F. Thomas, J. Wu, B. Paigen, et al. Hepatic ABCG5/G8 overexpression reduces apoB-lipoproteins and atherosclerosis when cholesterol absorption is inhibited J. Lipid Res., January 1, 2007; 48(1): 114 - 126. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. E. Hawes, K. A. O'Neill, X. Yao, J. H. Crona, H. R. Davis Jr., M. P. Graziano, and S. W. Altmann In Vivo Responsiveness to Ezetimibe Correlates with Niemann-Pick C1 Like-1 (NPC1L1) Binding Affinity: Comparison of Multiple Species NPC1L1 Orthologs Mol. Pharmacol., January 1, 2007; 71(1): 19 - 29. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Lalloyer, C. Fievet, S. Lestavel, G. Torpier, J. van der Veen, V. Touche, S. Bultel, S. Yous, F. Kuipers, R. Paumelle, et al. The RXR Agonist Bexarotene Improves Cholesterol Homeostasis and Inhibits Atherosclerosis Progression in a Mouse Model of Mixed Dyslipidemia Arterioscler Thromb Vasc Biol, December 1, 2006; 26(12): 2731 - 2737. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. P. Tam, J. B. Ancsin, R. Tan, and R. Kisilevsky Peptides derived from serum amyloid A prevent, and reverse, aortic lipid lesions in apoE-/- mice J. Lipid Res., October 1, 2005; 46(10): 2091 - 2101. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. A. Valasek, J. Weng, P. W. Shaul, R. G. W. Anderson, and J. J. Repa Caveolin-1 Is Not Required for Murine Intestinal Cholesterol Transport J. Biol. Chem., July 29, 2005; 280(30): 28103 - 28109. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Garcia-Calvo, J. Lisnock, H. G. Bull, B. E. Hawes, D. A. Burnett, M. P. Braun, J. H. Crona, H. R. Davis Jr., D. C. Dean, P. A. Detmers, et al. The target of ezetimibe is Niemann-Pick C1-Like 1 (NPC1L1) PNAS, June 7, 2005; 102(23): 8132 - 8137. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. J. Repa, S. D. Turley, G. Quan, and J. M. Dietschy Delineation of molecular changes in intrahepatic cholesterol metabolism resulting from diminished cholesterol absorption J. Lipid Res., April 1, 2005; 46(4): 779 - 789. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. N. van der Veen, J. K. Kruit, R. Havinga, J. F. W. Baller, G. Chimini, S. Lestavel, B. Staels, P. H. E. Groot, A. K. Groen, and F. Kuipers Reduced cholesterol absorption upon PPAR{delta} activation coincides with decreased intestinal expression of NPC1L1 J. Lipid Res., March 1, 2005; 46(3): 526 - 534. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. R. Davis Jr., L.-j. Zhu, L. M. Hoos, G. Tetzloff, M. Maguire, J. Liu, X. Yao, S. P. N. Iyer, M.-H. Lam, E. G. Lund, et al. Niemann-Pick C1 Like 1 (NPC1L1) Is the Intestinal Phytosterol and Cholesterol Transporter and a Key Modulator of Whole-body Cholesterol Homeostasis J. Biol. Chem., August 6, 2004; 279(32): 33586 - 33592. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. S. Meir and E. Leitersdorf Atherosclerosis in the Apolipoprotein E-Deficient Mouse: A Decade of Progress Arterioscler Thromb Vasc Biol, June 1, 2004; 24(6): 1006 - 1014. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Cai, E. R. M. Eckhardt, W. Shi, Z. Zhao, M. Nasser, W. J. S. de Villiers, and D. R. van der Westhuyzen Scavenger receptor class B type I reduces cholesterol absorption in cultured enterocyte CaCo-2 cells J. Lipid Res., February 1, 2004; 45(2): 253 - 262. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Lin, G. W. Meijer, M. A. Vermeer, and E. A. Trautwein Soy Protein Enhances the Cholesterol-Lowering Effect of Plant Sterol Esters in Cholesterol-Fed Hamsters J. Nutr., January 1, 2004; 134(1): 143 - 148. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. J. Repa, J. M. Dietschy, and S. D. Turley Inhibition of cholesterol absorption by SCH 58053 in the mouse is not mediated via changes in the expression of mRNA for ABCA1, ABCG5, or ABCG8 in the enterocyte J. Lipid Res., November 1, 2002; 43(11): 1864 - 1874. [Abstract] [Full Text] [PDF]
|
|